New combination tablet for type II diabetes

Janumet (sitagliptin/metformin) is a new fixed-dose combination treatment for patients with inadequately controlled type II diabetes.

PHARMACOLOGY

Janumet provides a fixed dose of two antidiabetic agents with complementary mechanisms of action: sitagliptin, a dipeptidyl peptidase 4 inhibitor and metformin, a member of the biguanide class.

CLINICAL STUDIES

Studies have proven the efficacy of sitagliptin in combination with metformin and/or a sulfonylurea. Three further studies were conducted to demonstrate the efficacy of Janumet.1

In 1091 patients who were not satisfactorily controlled on diet and exercise alone, Janumet reduced HbA1c levels after 24 weeks to a greater extent than metformin or sitagliptin alone.

In 278 patients inadequately controlled on metformin and rosiglitazone, addition of sitagliptin reduced HbA1c levels after 18 weeks to a greater extent than addition of placebo. Similarly, addition of sitagliptin produced greater HbA1c reductions after 24 weeks than addition of placebo in 641 patients inadequately controlled on a stable dose of insulin, with or without metformin.

View Janumet drug record

REFERENCES

  1. CHMP Assessment Report for Janumet. EMEA/H/C/000861.

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases